European CHMP recommends approval of glasdegib for the treatment of adults with acute myeloid leukaemia (AML)

Glasdegib is an inhibitor of the Hedgehog signal transduction pathway. It is intended for use in combination with low-dose cytarabine for the treatment of newly diagnosed de novo or secondary AML in adults who are not candidates for standard induction chemotherapy.


European Medicines Agency